Latest news

• Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

  The three biosimilars are: Mylan’s Hulio (adalimumab), a version of AbbVie’s big-selling Humira for the treatment of certain inflammatory and autoimmune disorders; and Accord Healthcare’s Pelgraz (pegfilgrastim) ... and ERA Consulting’s Udenyca

• Novartis doubles down on biosimilars with Biocon alliance

  drug Herceptin (trastuzumab) and Amgen's long-acting white cell booster Neulasta (pegfilgrastim) last August at the request of the EMA.

• Biocon backs away from biosimilar filings in Europe

  white cell booster Neulasta (pegfilgrastim) at the request of the EMA.

• Novartis says its biosimilar sales should reach $1bn this year

  The biosimilar is also under review in Europe. Meanwhile, Novartis confirmed that it will have to carry out a new clinical trial on its biosimilar version of Amgen's Neulasta (pegfilgrastim),

• Novartis gets FDA panel backing for biosimilar Enbrel

  The company has several other biosimilars in clinical development, including copycat versions of Humira, Roche's MabThera/Rituxan (rituximab), Amgen's Epogen (epoetin alfa) and Neulasta (pegfilgrastim) and Johnson &Johnson's